Navigation Links
Oncobiologics, Inc. Announces Two New Agreements Worth Close to $80 Million
Date:10/13/2011

CRANBURY, N.J., Oct. 13, 2011 /PRNewswire/ -- Oncobiologics announced today that it has signed two major agreements. The first is with Parilis Biopharmaceuticals, an early-stage biotech company, and involves worldwide licensing for an undisclosed biotherapeutic product. The second is with a US based large pharmaceutical company to conduct research focused on solving issues related to downstream processing of monoclonal antibodies. The identity of the client firm was not disclosed due to confidentiality terms in the agreement. The combined value of the agreements to Oncobiologics totals close to $80 million.

Dennis O'Donnell, CEO of Parilis Biopharmaceuticals said, "We are very excited about this agreement with Oncobiologics.  This is a major step for Parilis in selecting a biotherapeutic candidate with very high potential. Oncobiologics' capabilities will enhance our speed to market and provide a much greater chance for success. Oncobiologics gives us access to a team of senior scientists with decades of large pharma experience. We have every confidence that they have the knowledge and scientific rigor needed to help ensure our mutual success."

Oncobiologics Vice President of Business Development, Jeremy Caudill commented, "These programs represent a significant milestone for Oncobiologics. They are a validation of our dual strategies; as a fully integrated Biopharmaceutical company, as well as providing world-class proof-of-concept services to customers and partners."

Caudill added, "These agreements also recognize the strength and depth of the team assembled here at Oncobiologics. For a major pharmaceutical organization to entrust an important technical program of this scope reflects the confidence they have in our capabilities.  Likewise, Dennis O'Donnell brings a track-record of successes and has chosen Oncobiologics largely on the strength of our team."

About Oncobiologics, Inc.

Headquartered in Cranbury, N.J., Oncobiologics is utilizing a proprietary platform to develop a pipeline of next generation biotherapeutics focused on clinically validated targets in the therapeutic areas of oncology, immuno-oncology, and immunology. Oncobiologics provides world-class, turnkey proof-of-concept services that can take a partner's pre-clinical candidates from chemistry, manufacture and control development all the way through Phase II clinical trials. For more information, please visit www.oncobiologics.com or call 609-619-3990.


'/>"/>
SOURCE Oncobiologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oncobiologics, Inc. and Fox Chase Cancer Center Announce Co-Development of a Novel Cancer Therapy Platform
2. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
3. ULURU Inc. Announces Altrazeal® Agreement for the European Market
4. Mylan Announces Intention to Refinance Existing Secured Credit Facility
5. Health Industry Group Purchasing Association Announces Name Change to Healthcare Supply Chain Association (HSCA) to Reflect Expertise, Experience and Position Within Healthcare Supply Chain
6. I-Flow LLC, a Kimberly-Clark Health Care Company Announces Agreement for ON-Q® Products With HealthTrust Purchasing Group
7. Merit Medical Systems Announces Earnings Release Date/Time and Conference Call Information for the Third Quarter Ended September 30, 2011
8. Webcast Alert: Heska Announces Third Quarter 2011 Earnings Conference Call Webcast
9. Lilly Announces Changes in Senior Management
10. Innocoll Announces European Approval for CollaGUARD®, Surgical Adhesion Barrier
11. Soligenix Announces Formation of Pediatric Crohns Disease Medical Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... "FCPX editors can ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Final Cut Pro X users can now reveal the media of their ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
Breaking Medicine News(10 mins):